Targeting HIF-2 α in clear cell renal cell carcinoma: A promising therapeutic strategy.

@article{MartnezSez2017TargetingH,
  title={Targeting HIF-2 α in clear cell renal cell carcinoma: A promising therapeutic strategy.},
  author={Olga Mart{\'i}nez-S{\'a}ez and Pablo Gajate Borau and Teresa Alonso-Gordoa and Javier Molina-Cerrillo and Enrique Grande},
  journal={Critical reviews in oncology/hematology},
  year={2017},
  volume={111},
  pages={117-123}
}
The loss of the Von Hippel-Lindau tumor suppressor (VHL) is a key oncogenic event in the vast majority of patients with clear cell renal cell carcinoma (ccRCC). With the loss of the VHL protein (pVHL) function, the hypoxia inducible factor α (HIF-α) accumulates inside the tumor cell and dimerizes with HIF-β. The HIF-α/HIF-β complex transcriptionally activates hundreds of genes promoting the adaptation to hypoxia that is implicated in tumor development. There is growing evidence showing that HIF… CONTINUE READING